On Monday (Dec. 8), UK regulators approved the first-ever clinical trial investigating N, N-Dimethyltryptamine (more commonly known as DMT) for depression. The trial will be the first looking at the therapeutic benefits of DMT on its own.
The research will likely begin in the early part of next year, reports The Guardian. Scientists will first administer DMT to healthy participants who have never taken a psychedelic before—a common practice in research to ensure the drug is safe—before it’s administered to 36 patients with clinical depression.
The research will be modeled after the studies administering psilocybin, the psychoactive component in psychedelic mushrooms, to subjects at institutions like Johns Hopkins, NYU, and Imperial College London. Participants in the trial will receive a psychotherapy session both before the DMT experience, to prepare, and afterwards, to process what happened during their trip.
DoubleBlind presents: How to grow mushrooms online course. Let's Shroom!
Up until now, there’s only been one clinical trial looking at the therapeutic potential of DMT. It looked at the potential of ayahuasca, which contains DMT in it, for treatment-depression. The study which had just 29 patients found that a significant percentage of the patients who received ayahuasca, as opposed to the placebo, saw improvements in their depression following one trip.
Carol Routledge, chief scientific and medical officer at Small Pharma, the neuropharmaceutical company conducting the trial with Imperial College London, tells The Guardian that, in addition to major depression, they’re hopeful DMT could be a treatment for PTSD, obsessive compulsive disorder, treatment-resistant depression, and, perhaps, even substance abuse.
Shelby Hartman is DoubleBlind’s Co-Founder and Editor-in-Chief. Her work has appeared in Rolling Stone, VICE, Playboy, and Quartz, among others.
We have a small favor to ask. In 2020, more than five million readers like you visited DoubleBlind’s website. Many of them are suffering and simply seeking trusted information on how to use psychedelics to heal.
We started DoubleBlind two years ago at a time when even the largest magazines and media companies were cutting staff and going out of business. Friends and family said we were crazy. But we did it anyway, because we believe in it—deeply. We believe in the value of good journalism. And we believe in the extraordinary potential of psychedelics to reduce suffering. At the time we made a commitment: we will never have a paywall, we will never rely on advertisers we don’t believe in to fund our reporting, and we will always be accessible via email and social media to support people for free on their journeys with plant medicines.
To help us do this, if you feel called and can afford it, we ask you to consider making a monthly donation to DoubleBlind, starting at $1. In exchange, you’ll be invited to a monthly Zoom call with DoubleBlind’s co-founders, Shelby Hartman and Madison Margolin, where they’ll answer any questions you have about the psychedelic movement or your own journey with psychedelics. These Zoom calls also include special guests, some of the people who we love and respect most in the psychedelic space. Together, we brainstorm, collaborate, dialogue, and, simply, commune. Either way, please know that we value you as a member of our community. Make a gift now from as little as $1. Thank you.